Impax Laboratories, Inc. IPXL today announced that it and Teva
Pharmaceuticals USA, Inc. have reached agreement with Janssen Pharmaceuticals,
Inc. and ALZA Corporation (together, “ALZA”) to settle pending U.S. litigation
with regard to the production and sale of generic formulations of CONCERTA^®
(methylphenidate hydrochloride extended release tablets, 18 mg, 27 mg, 36 mg,
and 54 mg). Under the terms of the settlement, ALZA has agreed to grant Impax
and Teva a license to sell generic versions of CONCERTA^® on July 14, 2013 or
earlier under certain circumstances.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in